CY1111840T1 - Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson - Google Patents

Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson

Info

Publication number
CY1111840T1
CY1111840T1 CY20111100887T CY111100887T CY1111840T1 CY 1111840 T1 CY1111840 T1 CY 1111840T1 CY 20111100887 T CY20111100887 T CY 20111100887T CY 111100887 T CY111100887 T CY 111100887T CY 1111840 T1 CY1111840 T1 CY 1111840T1
Authority
CY
Cyprus
Prior art keywords
methoxy
carboxamide
pyridin
dichloro
pyridine
Prior art date
Application number
CY20111100887T
Other languages
Greek (el)
English (en)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1111840T1 publication Critical patent/CY1111840T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CY20111100887T 2007-04-19 2011-09-15 Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson CY1111840T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
EP08787963A EP2146714B1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
CY1111840T1 true CY1111840T1 (el) 2015-10-07

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100887T CY1111840T1 (el) 2007-04-19 2011-09-15 Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR101503942B1 (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ ４−（シクロプロピルメトキシ）−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−メトキシピリジン−２−カルボキサミドの結晶形態の製造方法およびその結晶形態
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
ES2362484T3 (es) * 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
EA019194B1 (ru) 2014-01-30
KR20150004885A (ko) 2015-01-13
NZ580482A (en) 2011-10-28
DK2146714T3 (da) 2011-10-10
AU2008257322A1 (en) 2008-12-04
EA200970970A1 (ru) 2010-02-26
BRPI0810444A2 (pt) 2016-05-31
JP5386478B2 (ja) 2014-01-15
FR2915100B1 (fr) 2009-06-05
KR101503942B1 (ko) 2015-03-18
CA2684174C (fr) 2014-02-25
EP2146714A1 (fr) 2010-01-27
KR20090130059A (ko) 2009-12-17
WO2008145841A1 (fr) 2008-12-04
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
RS51869B (sr) 2012-02-29
MY148092A (en) 2013-02-28
JP2010524906A (ja) 2010-07-22
PT2146714E (pt) 2011-09-02
AR066108A1 (es) 2009-07-22
PA8776801A1 (es) 2008-11-19
CL2008001136A1 (es) 2009-01-16
IL201448A0 (en) 2010-05-31
TWI439269B (zh) 2014-06-01
HRP20110666T1 (hr) 2011-10-31
FR2915100A1 (fr) 2008-10-24
CA2684174A1 (fr) 2008-12-04
JO2678B1 (en) 2013-03-03
ATE513548T1 (de) 2011-07-15
SI2146714T1 (sl) 2011-10-28
ZA200907251B (en) 2011-04-28
UY31035A1 (es) 2008-11-28
ME00935B (me) 2012-06-20
US20100130554A1 (en) 2010-05-27
TW200911247A (en) 2009-03-16
CN101663035A (zh) 2010-03-03
MX2009011284A (es) 2009-11-02
HK1141725A1 (en) 2010-11-19
EP2146714B1 (fr) 2011-06-22
PL2146714T3 (pl) 2011-10-31
ES2367408T3 (es) 2011-11-03
IL201448A (en) 2014-08-31
CN101663035B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
LTC2937350I2 (lt) 1'-pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
CY2016040I2 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CL2008000461A1 (es) Uso de aclidinio en el tratamiento o prevencion de una enfermedad o un estado respiratorio en un paciente por inhalacion, sin producir en dicho paciente efectos antimuscarinicos sistemicos.
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
BRPI0810774A2 (pt) composição de cuidado oral ou cuidado corporal.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
CY1111840T1 (el) Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson
DK2175877T3 (da) Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
SI1940409T1 (sl) Nove zdravilske kombinacije za zdravljenje bolezni dihalnih poti
CY1111779T1 (el) Χρηση του 4-κυκλοπροπυλομεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλο)-5-(μεθοξυ)πυριδινο-2-καρβοξαμιδιου για τη θεραπευτικη αντιμετωπιση των τραυματισμων του νωτιαιου μυελου
UA114486C2 (uk) Застосування 4-амінопіридину у лікуванні пов'язаної з інсультом сенсорно-рухової недостатності
CY1111534T1 (el) Χρηση αλατων τιοτροπιου στην αντιμετωπιση μετριου επιμονου ασθματος